ArticleJournal of neuropathology and experimental neurology2025
Neuropathologic findings in a community-based autopsy cohort of older, virally suppressed, people with HIV.
Article in Journal of neuropathology and experimental neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Central Nervous System T-cell immune architecture, and not HIV burden, tracks with cognition under long-term viral suppression.PLoS pathogens · 2026Article
- Interferon-induced protein IFIT3 as a molecular nexus of neuroinflammation in Alzheimer's disease and HIV-associated neurocognitive disorders.Journal of neuroinflammation · 2026Article
- HIV-1 Tat and gp120 as key drivers of neurodegeneration in the central nervous system.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Combination antiretroviral therapy (cART) has reduced the incidence of HIV-related mortality, leading to a growing population of older virally suppressed people with HIV (PWH). cART has also decreased the prevalence of HIV-associated dementia; however, many virally suppressed PWH still experience milder forms of cognitive impairment. It remains unclear whether aging virally suppressed PWH demonstrate distinct risks or patterns of neurodegenerative pathology. We examined brain tissue of 13 virally suppressed PWH and 13 matched HIV-negative controls from a community-based cohort and characterized β-amyloid (Aβ), tau, α-synuclein, and TDP-43 pathology. Both groups had similar demographics, medical comorbidities, and routine histologic brain findings. PWH demonstrated trends toward an increased prevalence of both Alzheimer disease (AD) and non-AD neurodegenerative pathologies, including Aβ pathology, higher stage tau pathology, aging-related tau astrogliopathy, and α-synuclein pathology. They showed similar trends toward increased severity of Aβ and tau pathology. We also identified a negative correlation between the burden of entorhinal cortical neurofibrillary tangles and end-of-life body mass index in PWH. Thus, PWH may have a greater burden of neurodegenerative pathology, including both AD and non-AD neurodegenerative pathologies; there is a need for the assessment of neurodegenerative pathology in community-based cohort studies to understand mechanisms of HIV-associated neuropathology and cognitive impairment in aging virally suppressed PWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.